<DOC>
	<DOCNO>NCT00268970</DOCNO>
	<brief_summary>The purpose trial study combination regimen satraplatin paclitaxel first-line treatment patient advance non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>Satraplatin Paclitaxel Patients With Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description>This trial design study efficacy safety novel oral platinum analog , satraplatin , combination another chemotherapy drug , paclitaxel , first line treatment ( patient receive chemotherapy disease metastasize ) patient advanced NSCLC . WHAT IS SATRAPLATIN : Satraplatin member platinum-based class chemotherapy drug . Platinum-based drug clinically prove one effective class anticancer therapy . Unlike currently market platinum-based drug , satraplatin give orally .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Satraplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Histologically confirm advanced NSCLC Patients must receive prior antineoplastic chemotherapy investigational product lung cancer prior study entry . Patients must least one unidimensionally measurable lesion definable magnetic resonance imaging ( MRI ) compute tomography ( CT ) scan . ECOG performance status â‰¤ 2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Advanced non-small cell lung cancer ( NSCLC )</keyword>
</DOC>